**AnBogen Therapeutics hits a milestone: completes USD 12.5M Series A funding round!**

In a strategic move led by CDIB Capital International Corporation, AnBogen Therapeutics proudly announces the successful closure of its Series A funding, amassing USD 12.5 million. Noteworthy contributors such as TaiAn Technologies Corporation Venture Capital, Maxpro Ventures and the NATIONAL DEVELOPMENT FUND, EXECUTIVE YUAN joined this significant funding round, propelling Anbogen into an exciting phase of growth.

Guided by the vision of General Manager Joe Hsueh (薛博仁) and under the leadership of CEO Dr. John Hsu (徐祖安) , Anbogen is gearing up to fast-track the development of its promising anti-cancer candidates, ABT-101 and ABT-301. Industry experts anticipate a debut on the Taipei Exchange by year-end as Anbogen continues its pursuit of groundbreaking biotech innovation. Stay updated on our journey by following #Globalbio.

Learn more: https://lnkd.in/gi9mAMRT